About the Company
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BBI News
Coinbase Cost Cuts, Netflix Earnings And Factor Investing: Forbes AI Newsletter - July 23rd
The company’s EPS numbers have grown by 8.43% over the past 12 months. Brickell Biotech Inc (BBI) – The pharmaceutical company is a Top Short for next week with our AI rating them an F in our ...
NKGen Biotech Inc NKGN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Largo Stock (NASDAQ:LGO), Quotes and News Summary
Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. Gainers Brickell Biotech ...
IO Biotech Inc IOBT
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Krystal Biotech Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
CENBF CEN Biotech, Inc.
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial ...
Edesa Biotech, Inc. (EDSA)
Revolving Line of Credit to Support Completion of Government-Funded ARDS StudyTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a ...
Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?
Over the last 30 days, two estimates have moved higher for Krystal Biotech, Inc. compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 180.68%. Current-Year ...
Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting ...
Susan Brickell
Susan Brickell is a senior e-commerce editor at Meredith, covering products in the form of reviews, roundups, and gift guides. She's been a market editor and writer for nearly a decade with her ...
Oncolytics Biotech Inc.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of ...
Oncolytics Biotech Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...